Sun Pharma Advanced Research Company Limited engages in the research and development of pharmaceutical products in India and internationally. The company develops new chemical entities or reformulated products based on its proprietary novel drug delivery systems. Its core therapeutic areas of interest include oncology, inflammation, and neurodegenerative diseases, as well as abuse deterrent formulations. The company offers Levetiracetam ER for epilepsy; and Xelpros eye drops for Glaucoma. It is also developing Taclantis for the treatment of cancer; salmeterol-fluticasone dry powder inhaler for use in asthma and COPD; Baclofen GRS for spasticity; Brimonidine OD for glaucoma and ocular hypertension; and SDN-037 steroid eye drops used for the treatment of pain and inflammation following ocular surgery, and other inflammatory ocular conditions. In addition, the company engages in the development of SCO-088, a Bcr–Abl kinase inhibitor for treatment resistant chronic myelogenous leukaemia (CML); SDN-021, an abuse deterrent formulation; and SCD-044, a S1P receptor-1 agonist, which uses lymphocyte trafficking to treat auto-immune disorders. Further, it develops SCC–138 for Parkinson's disease; SDN–118, a formulation for treating depression; SDD-098 to treat acne; and SDE-124, a sub cutaneous injection of GLP-1 receptor agonists, as well as SCO-125 to treat CML. Sun Pharma Advanced Research Company Limited has a collaboration agreement with Bioprojet to develop S1P receptor 1 agonist for autoimmune disorders; and HitGen to identify small molecule leads for targets of interest. The company was incorporated in 2006 and is based in Mumbai, India. Sun Pharma Advanced Research Company Limited is a subsidiary of Shanghvi Finance Pvt. Ltd. The ISIN of this stock is INE232I01014.